Neuroregulation of the hypothalamus-pituitary-adrenal (HPA) axis in humans: Effects of GABA-, mineralocorticoid-, and GH-secretagogue-receptor modulation

TheScientificWorldJournal

Volumn 6, Issue , 2006, Pages 1-11

  Giordano, Roberta ^a   Pellegrino, Micaela ^a   Picu, Andreea ^a   Bonelli, Lorenza ^a   Balbo, Marcella ^a   Berardelli, Rita ^a   Lanfranco, Fabio ^a   Ghigo, Ezio ^a   Arvat, Emanuela ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

ACTH; Benzodiazepines; Cortisol; Feedback; Ghrelin; GHS; Humans

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARGIPRESSIN; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CANRENOIC ACID; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; DIAZEPAM; GHRELIN; GLUCOCORTICOID RECEPTOR; GROWTH HORMONE SECRETAGOGUE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HEXARELIN; HYDROCORTISONE; HYPNOTIC AGENT; INSULIN; METYRAPONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MUSCLE RELAXANT AGENT; NALOXONE; 4 AMINOBUTYRIC ACID A RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; G PROTEIN COUPLED RECEPTOR;

ADDISON DISEASE; ANOREXIA NERVOSA; ANXIETY DISORDER; CIRCADIAN RHYTHM; CUSHING DISEASE; DEPRESSION; FEEDBACK SYSTEM; HIPPOCAMPUS; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS; NEUROENDOCRINE SYSTEM; NEUROTRANSMISSION; NONHUMAN; PANIC; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; HOMEOSTASIS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM;

ANIMALIA;

FEEDBACK; HOMEOSTASIS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEUROTRANSMITTER AGENTS; PITUITARY-ADRENAL SYSTEM; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GABA-A; RECEPTORS, MINERALOCORTICOID;

EID: 33645242869     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2006.09     Document Type: Review

References (60)

1. Jacobson, L. (2005) Hypothalamic-pituitary-adrenocortical axis regulation. Endocrinol. Metab. Clin. North Am. 34, 271-292.
2. Orth, D.N. (1992) Corticotropin-releasing hormone in humans. Endocr. Rev. 13, 164-191.
3. Jacobson, L. and Sapolsky, R. (1991) The role of the hippocampus in feedback regulation of the hypothalamic-pituitary adrenocortical axis. Endocr. Rev. 12, 118-134.
4. de Kloet, E.R., Vreugdenhil, E., Oitzl, M.S., and Joels, M. (1998) Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 19, 269-301.
5. Gaillard, R.C. and Al Damluji, S. (1987) Stress and the pituitary-adrenal axis. Baillieres Clin. Endocrinol. Metab. 1, 319-354.
6. Pasquali, R. and Vicennati, V. (2000) Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int. J. Obes. Relat. Metab. Disord. 24(Suppl 2), S47-S49.
7. Licinio, J., Wong, M.L., and Gold, P.W. (1996) The hypothalamic- pituitary-adrenal axis in anorexia nervosa. Psychiatry Res. 62, 75-83.
8. (1989) Benzodiazepines. In Brain Messengers and the Pituitary. Muller, E.E. and Nistico, G., Eds. Academic Press, San Diego, CA. p. 157.
9. Braestrup, C. and Nielsen, M. (1983) Benzodiazepine receptors. In Handbook of Psychopharmacology. Iverson, L., Iverson, S.D., and Snyder, S.M., Eds. Plenum Publishing, New York. p. 285.
10. Skerritt, J.H., Chow, S.C., and Johnston, G.A. (1982) Differences in the interactions between GABA and benzodiazepine binding sites. Neurosci. Lett. 33, 173-178.
11. Berman, J.A., Roberts, J.L., and Pritchett, D.B. (1994) Molecular and pharmacological characterization of GABA-A receptors in the rat pituitary. J. Neurochem. 63, 1948-1954.
12. Papadopoulos, V. (1993) Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: biological role in steroidogenic cell function. Endocr. Rev. 14, 222-240.
13. Pivac, N. and Pericic, D. (1993) Inhibitory effect of diazepam on the activity of the hypothalamic-pituitary-adrenal axis in female rats. J. Neural Trans. Gen. Sect. 92, 173-186.
14. Havard, C., Saldanha, V., Bird, R., and Gardner, R. (1972) The effect of diazepam on pituitary function in man. J. Endocrinol. 52, 79-85.
15. Brever, A., Charney, D.S., and Heninger, G.R. (1986) Intravenous diazepam fails to change growth hormone and cortisol secretion in humans. Psychiatry Res. 18, 298-299.
16. Von Voigtlander, P.F. and Straw, R.N. (1985) Alprazolam: review of pharmacological, pharmacokinetic, and clinical data. Drug Dev. Res. 6, 1-12.
17. Dawson, G.W., Jue, S.G., and Brogden, R.N. (1984) Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 27, 132-147.
18. Arvat, E., Giordano, R., Grottoli, S., and Ghigo, E. (2002) Benzodiazepines and anterior pituitary function. J. Endocrinol. Invest. 25, 735-747.
19. Arvat, E., Maccagno, B., Ramunni, J., Di Vito, L., Giordano, R., Gianotti, L., Broglio, F., Camanni, F., and Ghigo, E. (1999) The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulated effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. J. Clin. Endocrinol. Metab. 84, 2611-2615.
20. Arvat, E., Maccagno, B., Ramunni, J., Di Vito, L., Gianotti, L., Broglio, F., Benso, A., Deghenghi, R., Camanni, F., and Ghigo, E. (1998) Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans. Neuroendocrinology 67, 310-316.
21. Giordano, R., Grottoli, S., Brossa, P., Pellegrino, M., Destefanis, S., Lanfranco, F., Gianotti, L., Ghigo, E., and Arvat, E. (2003) Alprazolam-a (benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. Clin. Endocrinol. (Oxf.) 59, 314-320.
22. Kalogeras, K.T., Calogero, A.E., Kuribayashi, T., Khan, I., Gallucci, W.T., Kling, M.A., Chrousos, G.P., and Gold, P.W. (1990) In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary- adrenal function: pharmacological and clinical implications. J. Clin. Endocrinol. Metab. 70, 1462-1471.
23. Grottoli, S., Maccagno, B., Ramunni, J., Di Vito, L., Giordano, R., Gianotti, L., DeStefanis, S., Camanni, F., Ghigo, E., and Arvat, E. (2002) Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. J. Endocrinol. Invest. 25, 420-425.
24. Grigoriadis, D.E., Pearsall, D., and De Souza, E.B. (1989) Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing- factor receptors in rat brain and pituitary. Neuropsychopharmacology 2, 53-60.
25. Grottoli, S., Giordano, R., Maccagno, B., Pellegrino, M., Ghigo, E., and Arvat, E. (2002) The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J. Clin. Endocrinol. Metab. 87, 4616-4620.
26. Calogero, A.E., Kamilaris, T.C., Bernardini, R., Johnson, E.O., Chrousos, G.P., and Gold, P.W. (1990) Effects of peripheral benzodiazepine receptor ligands on hypothalamic-pituitary-adrenal axis function in the rat. J. Pharmacol. Exp. Ther. 253, 729-737.
27. Grottoli, S., Arvat, E., Gauna, C., Maccagno, B., Ramunni, J., Giordano, R., Maccario, M., Deghenghi, R., and Ghigo, E. (1999) Effects of alprazolam, a benzodiazepine, on the ACTH, GH, and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease. Pituitary 2, 197-204.
28. Funder, J.W. (1997) Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu. Rev. Med. 48, 231-240.
29. Ratka, A., Sutanto, W., Bloemers, M., and de Kloet, E.R. (1989) On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 50, 117-123.
30. Born, J., DeKloet, E.R., Wenz, H., Kern, W., and Fehm, H.L. (1991) Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am. J. Physiol. 260, E183-E188.
31. Arvat, E., Maccagno, B., Giordano, R., Pellegrino, M., Broglio, F., Gianotti, L., Maccario, M., Camanni, F., and Ghigo, E. (2001) Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. J. Clin. Endocrinol. Metab. 86, 3176-3181.
32. Wellhoener, P., Born, J., Fehm, H.L., and Dodt, C. (2004) Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. J. Clin. Endocrinol. Metab. 89, 5048-5052.
33. Wiedemann, K., Lauer, C., Pollmacher, T., and Holsboer, F. (1994) Sleep endocrine effects of antigluco- and antimineralocorticoids in healthy males. Am. J. Physiol. 267, E109-E114.
34. Sapolsky, R.M., Krey, L.C., and McEwen, B. (1986) The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr. Rev. 7, 284-301.
35. Seeman, T.E. and Robbins, R.J. (1994) Aging and hypothalamic-pituitary- adrenal response to challenge in humans. Endocr. Rev. 15, 233-260.
36. Wang, P.S., Lo, M.J., and Kau, M.M. (1997) Glucocorticoids and aging. J. Formos. Med. Assoc. 96, 792-801.
37. Kovacs, K.J. and Makara, G.B. (1988) Corticosterone and dexamethasone act at different brain sites to inhibit adrenalectomy-induced adrenocorticotropin hypersecretion. Brain Res. 474, 205-210.
38. Wilkinson, C.W., Peskind, E.R., and Raskind, M.A. (1997) Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Neuroendocrinology 65, 79-90.
39. Giordano, R., Bo, M., Pellegrino, M., Vezzari, M., Baldi, M., Picu, A., Balbo, M., Bonelli, L., Migliaretti, G., Ghigo, E., and Arvat. E. (2005) Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralcorticoid receptor blockade. J. Clin. Endocrinol. Metab. 90, 5656-5662.
40. Orentreich, N., Brind, J.L., Rizer, R.L., and Vogelman, J.K. (1984) Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59, 551-555.
41. Giordano, R., Di Vito, L., Lanfranco, F., Broglio, F., Benso, A., Gianotti, L., Grottoli, S., Ghigo, E., and Arvat, E. (2001) Elderly subjects show severe impairment of dehydroepiandrosterone sulphate and reduced sensitivity of cortisol and aldosterone response to the stimulatory effect of ACTH(1-24). Clin. Endocrinol. (Oxf.) 55, 259-265.
42. Young, E.A., Lopez, J.F., Murphy-Weinberg, V., Watson, S.J., and Akil. H. (2003) Mineralcorticoid receptor function in major depression. Arch. Gen. Psychiatry 60, 24-28.
43. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K. (1999) Ghrelin is a growth hormone-releasing acylated peptide from stomach. Nature 402, 656-660.
44. Van der Lely, A.J., Tschop, M., Heiman, M.L., and Ghigo, E. (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 25, 426-457.
45. Korbonits, M., Goldstone, A.P., Gueorguiev, M., and Grossman, A.B. (2004) Ghrelin a hormone with multiple functions. Front. Neuroendocrinol. 25, 27-68.
46. Ghigo, E., Broglio, F., Arvat, E., Maccario, M., Papotti, M., and Muccioli, G. (2005) Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin. Endocrinol. 62, 1-17.
47. Gnanapavan, S., Kola, B., Bustin, S.A., Morris, D.G., McGee, P., Fairclough, P., Bhattacharya, S., Carpenter, R., Grossman, A.B., and Korbonits, M. (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 87, 2988.
48. Muccioli, G., Papotti, M., Locatelli, V., Ghigo, E., and Deghenghi, R. (2001) Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J. Endocrinol. Invest. 24, RC7-RC9.
49. Tassone, F., Broglio, F., Destefanis, S., Rovere, S., Benso, A., Gottero, C., Prodam, F., Rossetto, R., Gauna, C., van der Lely, A.J., Ghigo, E., and Maccario, M. (2003) Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. J. Clin. Endocrinol. Metab. 88, 5478-5483.
50. Broglio, F., Gianotti, L., Destefanis, S., Fassino, S., Abbate, D.G., Mondelli, V., Lanfranco, F., Gottero, C., Gauna, C., Hofland, L., van der Lely, A.J., and Ghigo, E. (2004) The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin. Endocrinol. 60, 592-599.
51. Arvat, E., Ramunni, J., Bellone, J., Di Vito, L., Baffoni, C., Broglio, F., Deghenghi, R., Bartolotta, E., and Ghigo, E. (1997) The GH, prolactin, ACTH and cortisol responses to hexarelin, a synthetic hexapeptide, undergo different agerelated variations. Eur. J. Endocrinol. 137, 635-642.
52. Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Fujimiya, M., Katsuura, G., Makino, S., Fujino, M.A., and Kasuga, M. (2001) A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 74, 143-147.
53. Arvat, E., Maccagno, B., Ramunni, J., Broglio, F., Lanfranco, F., Giordano, R., Benso, A., Deghenghi, R., and Ghigo, E. (1998) Influence of galanin and serotonin on the endocrine response to hexarelin, a synthetic peptidyl GHsecretagogue, in normal women. J. Endocrinol. Invest. 21, 673-679.
54. Arvat, E., Ramunni, J., Maccagno, B., Giordano, R., Broglio, F., Deghenghi, R., Boscaro, M., and Ghigo, E. (1999) Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease. Neuroendocrinology 70, 200-206.
55. Ghigo, E., Arvat, E., Ramunni, J., Colao, A., Gianotti, L., Deghenghi, R., Lombardi, G., and Camanni, F. (1997) Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J. Clin. Endocrinol. Metab. 82, 2439-2444.
56. Arvat, E., Giordano, R., Ramunni, J., Arnaldi, G., Colao, A., Deghenghi, R., Lombardi, G., Mantero, F., Camanni, F., and Ghigo, E. (1998) Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. J. Clin. Endocrinol. Metab. 83, 4207-4211.
57. Leal-Cerro, A., Torres, E., Soto, A., Dios, E., Deghenghi, R., Arvat, E., Ghigo, E., Dieguez, C., and Casanueva, F.F. (2002) Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses. Neuroendocrinology 76, 390-396.
58. Giordano, R., Picu, A., Pagotto, U., De Iasio, R., Bonelli, L., Prodam, F., Broglio, F., Marafetti, L., Pasquali, R., Maccario, M., Ghigo, E., and Arvat, A. (2005) The negative association between total ghrelin levels and body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease. Eur. J. Endocrinol. 153, 535-543.
59. Korbonits, M., Bustin, S.A., Kojima, M., Jordan, S., Adams, E.F., Lowe, D.G., Kangawa, K., and Grossman, A.B. (2001) The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J. Clin. Endocrinol. Metab. 86, 881-887.
60. Arnaldi, G., Mancini, T., Kola, B., Appolloni, G., Freddi, S., Concettoni, C., Bearzi, I., Masini, A., Boscaro, M., and Mantero, F. (2003) Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors. J. Clin. Endocrinol. Metab. 88, 5834-5840.